{"id":508,"date":"2018-09-11T15:37:38","date_gmt":"2018-09-11T19:37:38","guid":{"rendered":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg"},"modified":"2022-02-07T15:05:57","modified_gmt":"2022-02-07T20:05:57","slug":"neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities","status":"inherit","type":"attachment","link":"https:\/\/www.lifetein.com\/blog\/neoepitopes-as-cancer-immunotherapy-targets\/neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities\/","title":{"rendered":"Neoepitopes-as-cancer-immunotherapy-targets–key-challenges-and-opportunities"},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"class_list":["post-508","attachment","type-attachment","status-inherit","hentry"],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\n","aioseo_head_json":{"title":"Neoepitopes-as-cancer-immunotherapy-targets\u2013key-challenges-and-opportunities | LifeTein Peptide Blog","description":"Neoepitopes as cancer immunotherapy targets","canonical_url":"https:\/\/www.lifetein.com\/blog\/neoepitopes-as-cancer-immunotherapy-targets\/neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"xKDW6DUiGuZ6nwglNeWlVWTgzTtMPzas13ROL63ytTc","msvalidate.01":"5B15601215D876311F84CFEFB0F72F18","miscellaneous":""},"schema":null,"og:locale":"en_US","og:site_name":"LifeTein Peptide Synthesis Blog","og:type":"article","og:title":"Neoepitopes-as-cancer-immunotherapy-targets\u2013key-challenges-and-opportunities | LifeTein Peptide Blog","og:description":"Neoepitopes as cancer immunotherapy targets","og:url":"https:\/\/www.lifetein.com\/blog\/neoepitopes-as-cancer-immunotherapy-targets\/neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities\/","fb:admins":"233983946638783","og:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","og:image:secure_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg","article:published_time":"2018-09-11T19:37:38+00:00","article:modified_time":"2022-02-07T20:05:57+00:00","article:publisher":"https:\/\/www.facebook.com\/LifeTein-LLC-233983946638783\/","twitter:card":"summary_large_image","twitter:site":"@lifetein","twitter:title":"Neoepitopes-as-cancer-immunotherapy-targets\u2013key-challenges-and-opportunities | LifeTein Peptide Blog","twitter:description":"Neoepitopes as cancer immunotherapy targets","twitter:creator":"@lifetein","twitter:image":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2020\/02\/LifeTein-Blog1-2-scaled.jpg"},"aioseo_meta_data":{"post_id":"508","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":true,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":null,"schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"none","priority":null,"frequency":null,"location":null,"local_seo":null,"seo_analyzer_scan_date":null,"breadcrumb_settings":null,"limit_modified_date":false,"open_ai":null,"ai":null,"created":"2020-12-04 22:27:30","updated":"2025-06-18 01:58:55"},"aioseo_breadcrumb":"
\n\t\t\tHome<\/a>\n\t\t<\/span>»<\/span>\n\t\t\tNeoepitopes-as-cancer-immunotherapy-targets\u2013key-challenges-and-opportunities\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.lifetein.com\/blog"},{"label":"Neoepitopes-as-cancer-immunotherapy-targets–key-challenges-and-opportunities","link":"https:\/\/www.lifetein.com\/blog\/neoepitopes-as-cancer-immunotherapy-targets\/neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities\/"}],"filename":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg","filesize":145083,"description":{"rendered":"

\"Neoepitopes<\/a><\/p>\n

The neoepitopes are very frequent in all cancers. Amino acid substitutions can yield neoantigens that are detected by the immune system. So the neoantigens have been used for the therapeutic purposes such as identifying cancer variant peptides for diagnosis and treatment.<\/p>\n"},"caption":{"rendered":"

Neoepitopes as cancer immunotherapy targets Continue reading →<\/span><\/a><\/p>\n"},"alt_text":"Neoepitopes as cancer immunotherapy targets: key challenges and opportunities","media_type":"image","mime_type":"image\/jpeg","media_details":{"width":1920,"height":989,"file":"2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg","sizes":{"thumbnail":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-150x150.jpg","width":150,"height":150,"filesize":5017,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-150x150.jpg"},"medium":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-300x155.jpg","width":300,"height":155,"filesize":9297,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-300x155.jpg"},"medium_large":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-768x396.jpg","width":768,"height":396,"filesize":36960,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-768x396.jpg"},"large":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1024x527.jpg","width":1024,"height":527,"filesize":54691,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1024x527.jpg"},"post-thumbnail":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1000x288.jpg","width":1000,"height":288,"filesize":38456,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1000x288.jpg"},"large-feature":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1000x288.jpg","width":1000,"height":288,"filesize":38456,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-1000x288.jpg"},"small-feature":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-500x258.jpg","width":500,"height":258,"filesize":20142,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities-500x258.jpg"},"full":{"file":"Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg","width":1920,"height":989,"mime_type":"image\/jpeg","source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg"}},"image_meta":{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0","keywords":[]},"filesize":145083},"post":507,"source_url":"https:\/\/www.lifetein.com\/blog\/wp-content\/uploads\/2018\/09\/Neoepitopes-as-cancer-immunotherapy-targets-key-challenges-and-opportunities.jpg","_links":{"self":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media\/508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/comments?post=508"}],"wp:attached-to":[{"embeddable":true,"post_type":"post","id":507,"href":"https:\/\/www.lifetein.com\/blog\/wp-json\/wp\/v2\/posts\/507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}